日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3

PALOMA-2 和 -3 研究分析了接受帕博西尼联合内分泌治疗的激素受体阳性/人表皮生长因子受体 2 阴性晚期乳腺癌日本患者的后续治疗情况。

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-020-01162-4
Masuda, Norikazu; Mukai, Hirofumi; Inoue, Kenichi; Rai, Yoshiaki; Ohno, Shinji; Ohtani, Shoichiro; Shimizu, Chikako; Hashigaki, Satoshi; Muramatsu, Yasuaki; Umeyama, Yoshiko; Iwata, Hiroji; Toi, Masakazu
肿瘤
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2021
文献求助 收藏

Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study

帕博西尼联合来曲唑作为晚期乳腺癌一线治疗方案：一项日本 II 期研究的最新结果

期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.3091
Takahashi, Masato; Masuda, Norikazu; Nishimura, Reiki; Inoue, Kenichi; Ohno, Shinji; Iwata, Hiroji; Hashigaki, Satoshi; Muramatsu, Yasuaki; Umeyama, Yoshiko; Toi, Masakazu
肿瘤
肿瘤免疫
乳腺癌
发表日期：2020
文献求助 收藏

Neutropenia management with palbociclib in Japanese patients with advanced breast cancer

帕博西尼治疗日本晚期乳腺癌患者的中性粒细胞减少症

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-019-00970-7
Masuda, Norikazu; Mukai, Hirofumi; Inoue, Kenichi; Rai, Yoshiaki; Ohno, Shinji; Mori, Yuko; Hashigaki, Satoshi; Muramatsu, Yasuaki; Umeyama, Yoshiko; Iwata, Hiroji; Toi, Masakazu
肿瘤
中性粒细胞
肿瘤免疫
乳腺癌
粒细胞
细胞生物学
发表日期：2019
文献求助 收藏

Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer

更正：关于使用帕博西尼治疗日本晚期乳腺癌患者的中性粒细胞减少症

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-019-00984-1
Masuda, Norikazu; Mukai, Hirofumi; Inoue, Kenichi; Rai, Yoshiaki; Ohno, Shinji; Mori, Yuko; Hashigaki, Satoshi; Muramatsu, Yasuaki; Umeyama, Yoshiko; Iwata, Hiroji; Toi, Masakazu
肿瘤
中性粒细胞
肿瘤免疫
乳腺癌
粒细胞
细胞生物学
发表日期：2019
文献求助 收藏

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients

帕博西尼联合氟维司群治疗激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌患者：PALOMA-3研究日本患者的亚组分析

期刊:International Journal of Clinical Oncology
影响因子:2.8
doi:10.1007/s10147-018-1359-3
Masuda, Norikazu; Inoue, Kenichi; Nakamura, Rikiya; Rai, Yoshiaki; Mukai, Hirofumi; Ohno, Shinji; Hara, Fumikata; Mori, Yuko; Hashigaki, Satoshi; Muramatsu, Yasuaki; Nagasawa, Takashi; Umeyama, Yoshiko; Huang, Xin; Iwata, Hiroji
肿瘤
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2019
文献求助 收藏

Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients

帕博西尼联合来曲唑治疗雌激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌患者：PALOMA-2研究日本患者的亚组分析

期刊:International Journal of Clinical Oncology
影响因子:2.8
doi:10.1007/s10147-018-1353-9
Mukai, Hirofumi; Shimizu, Chikako; Masuda, Norikazu; Ohtani, Shoichiro; Ohno, Shinji; Takahashi, Masato; Yamamoto, Yutaka; Nishimura, Reiki; Sato, Nobuaki; Ohsumi, Shozo; Iwata, Hiroji; Mori, Yuko; Hashigaki, Satoshi; Muramatsu, Yasuaki; Nagasawa, Takashi; Umeyama, Yoshiko; Lu, Dongrui R; Toi, Masakazu
肿瘤
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2019
文献求助 收藏

Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor

更正：舒尼替尼治疗日本不可切除或转移性、高分化胰腺神经内分泌肿瘤患者的II期研究

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-019-00757-9
Ito, Tetsuhide; Okusaka, Takuji; Nishida, Toshirou; Yamao, Kenji; Igarashi, Hisato; Morizane, Chigusa; Kondo, Shunsuke; Mizuno, Nobumasa; Hara, Kazuo; Sawaki, Akira; Hashigaki, Satoshi; Kimura, Nobuyuki; Murakami, Mami; Ohki, Emiko; Chao, Richard C; Imamura, Masayuki
肿瘤
肿瘤免疫
发表日期：2019
文献求助 收藏

Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study

舒尼替尼治疗日本进展期、晚期/转移性、高分化、不可切除胰腺神经内分泌肿瘤患者的疗效和安全性：一项II期研究的最终分析

期刊:Japanese Journal of Clinical Oncology
影响因子:2.2
doi:10.1093/jjco/hyz009
Ito, Tetsuhide; Tori, Masayuki; Hashigaki, Satoshi; Kimura, Nobuyuki; Sato, Kazuo; Ohki, Emiko; Sawaki, Akira; Okusaka, Takuji
肿瘤
肿瘤免疫
发表日期：2019
文献求助 收藏

Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study

帕博西尼联合来曲唑作为晚期乳腺癌一线治疗：一项日本 II 期研究

期刊:Cancer Science
影响因子:4.3
doi:10.1111/cas.13507
Masuda, Norikazu; Nishimura, Reiki; Takahashi, Masato; Inoue, Kenichi; Ohno, Shinji; Iwata, Hiroji; Mori, Yuko; Hashigaki, Satoshi; Muramatsu, Yasuaki; Nagasawa, Takashi; Umeyama, Yoshiko; Toi, Masakazu
肿瘤
肿瘤免疫
乳腺癌
发表日期：2018
文献求助 收藏

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

克唑替尼与化疗在亚洲ALK阳性晚期非小细胞肺癌患者中的疗效比较

期刊:Cancer Research and Treatment
影响因子:3.8
doi:10.4143/crt.2017.280
Nishio, Makoto; Kim, Dong-Wan; Wu, Yi-Long; Nakagawa, Kazuhiko; Solomon, Benjamin J; Shaw, Alice T; Hashigaki, Satoshi; Ohki, Emiko; Usari, Tiziana; Paolini, Jolanda; Polli, Anna; Wilner, Keith D; Mok, Tony
肺癌
肿瘤
肿瘤免疫
ALK
细胞生物学
发表日期：2018
文献求助 收藏